Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Bill Anderson's replacement as chief executive of Roche Pharmaceuticals has been announced, with head of global product strategy Teresa Graham stepping up into the role. Anderson's departure was ...

Quickly build AI-enabled business solutions that help streamline workflows and enhance productivity using Copilot in Microsoft Power Platform. Empower everyone in your business to rapidly develop apps ...

Search the most accurate and complete listings in the industry. Get an online offer in 2 minutes using our Sell My Car tool.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...